Vitrolife Ab · OMXSTO:VITR
Vitrolife Ab — Investor Presentation (May 2025)
11 slides from Vitrolife Ab's investor presentation, May 21, 2025
Slide 1: Vitrolife AB (publ) Investor presentation
Vitrolife AB (publ) Investor presentation 2025-05-21 2025-05-22
Slide 2: The sheer magnitude of the global infertility healthcare issue
The sheer magnitude of the global infertility healthcare issue Adults >20 years old Adults >20 living Adults affected Coronary artery disease with Diabetes by infertility 2 Source: CDC International Diabetes Foundation, ESHRE, SART
Slide 3: Significant market opportunity in reproductive health
Significant market opportunity in reproductive health Successful treatment outcomes ~33% *** 1 in 6 134 M Access and affordability constraining ~5% people globally is babies born annually** estimated cycle growth affected by infertility* < 1% via IVF growth in coming years *Source: World Health Organ
Slide 4: Key IVF market dynamics
Key IVF market dynamics Growth in demand Need to increase IVF capacity & accessibility Clinics labor and skills shortage Automation & digitalization required Consolidation of clinics Standardization and scalability is a must Diverse portfolio to address differences in Regionalisation of standards of
Slide 5: 5 Strategic Pillars focusing on Innovation, Growth and Operational Excellence
5 Strategic Pillars focusing on Innovation, Growth and Operational Excellence INNOVATION GROWTH OPERATIONS 1 2 3 4 5 Own the platform Innovate to Accelerate Optimise go-to- Drive operational connecting expand growth in key market model excellence products and leadership markets services • Drive embr
Slide 6: Revenue per segment and product group Q1 2025
Revenue per segment and product group Q1 2025 Consumables APAC 41% 28% Americas 32% Genetics 41% Revenue by Revenue by geography product groups EMEA Technologies 40% 18% Good geographic balance has proved critical in Well balanced from a product group perspective. the changing macroeconomic enviro
Slide 7: Focus for 2025
Focus for 2025 1. Continue to drive share gain in key markets leveraging the full breadth of the portfolio. 2. Accelerate penetration of our combined EmbryoScope and lab control solutions. Growth 3. Deliver best in class quality and customer service to further differentiate from competitors. 1. Prio
Slide 8: Tariff update as per May 12th
Tariff update as per May 12th Current status: • US: Imposed 145% tariffs on Chinese, currently 30% due to 90 days pause, and 20% on EU (currently a 90 days pause -10% applies) medical devices to promote domestic manufacturing. • EU: Planning retaliatory tariffs up to 25% on U.S. goods, possibly incl
Slide 9: Background on PGT-A: In a nutshell
Background on PGT-A: In a nutshell What are the Steps Required for patients to be performed PGT-A during What is PGT-A test? their IVF Process? PGT-A is a genetic study of the embryo produced during IVF First step is Patients visiting IVF Clinic/Physician. treatment to identify numerical chromosom
Slide 10: Reasons to invest in Vitrolife AB (publ)
Reasons to invest in Vitrolife AB (publ) • Underlying resilient market growth. • High quality brands linked with outstanding service and support. • Proven track record of profitable growth. • Innovation and technology leader within fertility. • Ambitious strategy and long-term objectives. Contact: in
Slide 11: Disclaimer
Disclaimer This presentation may contain estimates and forward-looking statements, which reflect the Management’s current views with respect to the market, certain future events and financial performance. Although the statements are based upon estimates the Management believes to be reasonable, there